Previous 10 | Next 10 |
Gainers: Day One Biopharmaceuticals (DAWN) +103%. Redbox Entertainment (RDBXW) +85%. OptiNose (OPTN) +37%. Cerberus Cyber Sentinel Corporation (CISO) +36%. Ekso Bionics Holdings (EKSO) +35%. AeroClean Technologies (AERC) +33%. Redbox Entertainment (RDBX) +29%. Electro-Sensors (ELSE) +17%. Cyn...
OptiNose (NASDAQ:OPTN) added 36% in the morning hours Monday after the commercial-stage pharma company announced Phase 3 data to indicate that its FDA-approved therapy for nasal polyps, Xhance was effective in chronic sinusitis patients. A drug-device combination to deliver topical ...
Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%. Neptune Wellness Solutions (NEPT) -19%. Sc...
Day One Biopharmaceuticals (DAWN) +81% announces positive initial data from pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Redbox Entertainment (RDBX) +30%. Ekso Bionics Holdings (EKSO) +22% receives FDA clearance to market its EksoNR Robotic...
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCE’s Current Nasal Polyps Indication and the...
Specialty pharmaceutical company Optinose (NASDAQ:OPTN) has announced the departure of CFO Keith Goldan, effective June 10, 2022. Goldan has accepted a CFO opportunity at another public company. VP Finance Michele Janis will now serve as acting CFO, while Anthony Krick, Vice President, Contro...
Michele Janis Appointed Acting Chief Financial Officer Anthony Krick Appointed Vice President & Chief Accounting Officer YARDLEY, Pa., June 03, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and th...
The following slide deck was published by OptiNose, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: OptiNose, Inc. 2022 Q1 - Results - Earnings Call Presentation
OptiNose, Inc. (OPTN) Q1 2022 Earnings Conference Call May 12, 2022, 08:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Keith Goldan - CFO Vic Clavelli - Chief Commercial Officer Ramy Mahmoud - President and COO Conference Call Participants Stacey Ku - Cowen Dave Amsellem...
OptiNose press release (NASDAQ:OPTN): Q1 GAAP EPS of -$0.31. Revenue of $14.76M (+23.4% Y/Y). The Company had cash and cash equivalents of $91.4 million as of March 31, 2022. Corporate Guidance: The Company expects XHANCE net revenues for the full year of 2022 to be at least $90 million...
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...